Your session is about to expire
What is Pomalidomide
PomalidomideThe Generic name of this drug
Treatment SummaryPomalidomide is a medication that works to treat cancer by changing how the immune system works. It is similar to thalidomide and was approved by the FDA in 2013.
Pomalystis the brand name
Pomalidomide Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Pomalyst
Pomalidomide
2013
4
Approved as Treatment by the FDA
Pomalidomide, otherwise known as Pomalyst, is approved by the FDA for 4 uses including Multiple Myeloma and Multiple Myeloma .Multiple Myeloma
Used to treat Trialled at least two prior therapies including lenalidomide and a proteasome inhibitor in combination with Dexamethasone
Multiple Myeloma
Used to treat Multiple Myeloma (MM) in combination with Dexamethasone
Multiple Myeloma (MM)
Used to treat Multiple Myeloma (MM) in combination with Dexamethasone
Trialled at least two prior therapies including lenalidomide and a proteasome inhibitor
Used to treat Trialled at least two prior therapies including lenalidomide and a proteasome inhibitor in combination with Dexamethasone
Effectiveness
How Pomalidomide Affects PatientsPomalidomide is much stronger than the drugs thalidomide and lenalidomide, being 100 times more potent than thalidomide and 10 times more potent than lenalidomide.
How Pomalidomide works in the bodyPromalidomide modifies the immune system to fight cancer. It stops the growth and reproduction of tumor cells, and increases the ability of T cells and natural killer cells to fight cancer. It also reduces inflammation by preventing the production of certain proteins. The primary way it works is by binding to a protein called cereblon and blocking its ability to produce certain molecules. It also stops the production of a molecule involved in inflammation.
When to interrupt dosage
The amount of Pomalidomide is contingent upon the identified illness. The amount of dosage is contingent upon the technique of delivery (e.g. Oral or Capsule) recorded in the table beneath.Condition
Dosage
Administration
Multiple Myeloma
, 1.0 mg, 2.0 mg, 3.0 mg, 4.0 mg
, Capsule, Oral, Capsule - Oral
Acquired Immunodeficiency Syndrome
, 1.0 mg, 2.0 mg, 3.0 mg, 4.0 mg
, Capsule, Oral, Capsule - Oral
Kaposi Sarcoma
, 1.0 mg, 2.0 mg, 3.0 mg, 4.0 mg
, Capsule, Oral, Capsule - Oral
HIV Vaccine
, 1.0 mg, 2.0 mg, 3.0 mg, 4.0 mg
, Capsule, Oral, Capsule - Oral
Multiple Myeloma
, 1.0 mg, 2.0 mg, 3.0 mg, 4.0 mg
, Capsule, Oral, Capsule - Oral
Warnings
There are 20 known major drug interactions with Pomalidomide.Common Pomalidomide Drug Interactions
Drug Name
Risk Level
Description
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Pomalidomide is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Acteoside
Major
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Acteoside.
Antilymphocyte immunoglobulin (horse)
Major
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Antilymphocyte immunoglobulin (horse).
Azelastine
Major
Pomalidomide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Bacillus calmette-guerin substrain russian BCG-I live antigen
Major
The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Pomalidomide.
Pomalidomide Toxicity & Overdose RiskCommon side effects of this drug include tiredness, low levels of white blood cells, anemia, constipation, nausea, diarrhea, shortness of breath, upper respiratory infections, back pain, and fever.
Pomalidomide Novel Uses: Which Conditions Have a Clinical Trial Featuring Pomalidomide?
17 active investigations are underway to assess the potential of Pomalidomide in providing relief from Refractory Multiple Myeloma.Condition
Clinical Trials
Trial Phases
Kaposi Sarcoma
8 Actively Recruiting
Phase 1, Phase 2
Multiple Myeloma
6 Actively Recruiting
Phase 1, Phase 2
Multiple Myeloma
0 Actively Recruiting
HIV Vaccine
0 Actively Recruiting
Acquired Immunodeficiency Syndrome
3 Actively Recruiting
Phase 1, Phase 2, Not Applicable
Pomalidomide Reviews: What are patients saying about Pomalidomide?
5Patient Review
1/22/2016 This treatment is effective with minimal side effects.
Patient Q&A Section about pomalidomide
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.Is pomalidomide a chemotherapy?
"The trade name for the drug Pomalyst is Pomalidomide. Health care professionals may use either the trade name or the generic name when referring to the drug."
Answered by AI
What class of drug is pomalidomide?
"Pomalidomide is an immunomodulatory drug that helps the bone marrow produce normal blood cells and kills abnormal cells in the bone marrow."
Answered by AI
Is pomalidomide better than lenalidomide?
"Pomalidomide is felt to be the most potent immunomodulatory drug (IMiD): 100 times the strength of thalidomide and 10 times that of lenalidomide [Gertz, 2013]. Cereblon expression by gene expression profiling was recently evaluated in 53 patients with relapsed/refractory myeloma treated with pomalidomide and dexamethasone [Schuster et al. 2012]."
Answered by AI
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.